Nubain, Nalbuphine

Nubain, Nalbuphine Newswire

Comprehensive Real-Time News Feed for Nubain, Nalbuphine (generic).

Results 1 - 20 of 32 in Nubain, Nalbuphine (generic)

  1. Budding Biotech In New Haven Receives $15 Million LoanRead the original story w/Photo

    Thursday Jan 8 | The Hartford Courant

    A budding pharmaceutical company in New Haven received a $15 million loan that will allow it to finish clinical trials on a treatment for chronic itching associated with kidney dialysis and, separately, a rare skin condition marked by hard, crusty bumps. Trevi Therapeutics Inc. of New Haven was formed in 2012 and is in late-stage development of its drug, Nalbuphine ER.

    Comment?

  2. Trevi Therapeutics Closes $15 Million Debt Facility Provided by Solar Capital and Square 1 BankRead the original story

    Wednesday Jan 7 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. 'This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis,' said Jennifer Good, President and CEO.

    Comment?

  3. Trevi Therapeutics Closes $15 Million Debt Facility Provided By AndRead the original story

    Wednesday Jan 7 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. "This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis," said Jennifer Good, President and CEO.

    Comment?

  4. Trevi closes $15 mln loan from Solar Capital and Square 1 BankRead the original story w/Photo

    Thursday Jan 8 | PE Hub

    January 8, 2015 - Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. "This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis," said Jennifer Good, President and CEO.

    Comment?

  5. Trevi Therapeutics Closes $15 Million Debt Facility Provided by Solar...Read the original story w/Photo

    Thursday Jan 8 | Investor's Business Daily

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced the closing of a $15 million senior secured term loan agreement provided by Solar Capital Ltd. as collateral agent and lender and Square 1 Bank as lender. "This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis," said Jennifer Good, President and CEO.

    Comment?

  6. Trevi Therapeutics To Present At The Healthcare ConferenceRead the original story

    Sunday Jan 4 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, today announced that Jennifer Good, President and Chief Executive Officer, will present a corporate overview of Trevi at the 33rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA on Thursday, January 15, 2015 at 8:30 am ET.

    Comment?

  7. Antinociceptive and cytotoxic activities of an epiphytic medicinal orchid: Vanda tessellata Roxb.Read the original story

    Dec 3, 2014 | BioMed Central

    Vanda tessellata has been used in different sorts of ailments such as inflammations, rheumatism, dysentery, bronchitis, dyspepsia and fever in folk medicine. In this study we evaluated the antinociceptive and cytotoxic effect of methanol and aqueous extracts of V. tessellata leaf.

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Nov 17, 2014 | Business Wire

    Company units were up 2.6%. )--Clear Channel Spectacolor, bedrijfsonderdeel van Clear Channel Outdoor , dochtermaatschappij van iHeartMedia Inc. , heeft vandaag het grootste, mee... )--Fitch Ratings has assigned an 'A+' rating to Duke Energy Progress, Inc.'s proposed new $700 million dual tranche offering of first mortgage bonds.

    Comment?

  9. Trevi Therapeutics to Present at the Stifel 2014 Healthcare ConferenceRead the original story

    Nov 17, 2014 | Business Wire

    Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus . Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions.

    Comment?

  10. Clinical Trial Website Launches in Support of Pivotal Trial in Prurigo NodularisRead the original story

    Nov 14, 2014 | Freshnews

    MediciGlobal has launched a new website on behalf of Trevi Therapeutics, Inc. to provide access to information on a clinical trial for prurigo nodularis, considered one of the most severe forms of pruritus . Prurigo nodularis, also known as nodular prurigo, is characterized by painful nodules that itch so intensely that the perpetual cycle of itch, scratch, bleed, and scarring lasts for years or even decades.

    Comment?

  11. Trevi Therapeutics Selected to Exhibit Poster at American Society of Nephrology Kidney Week 2014Read the original story

    Nov 11, 2014 | Customer Interaction Solutions

    Trevi Therapeutics, Inc. , a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus conditions, was selected to exhibit a poster at the American Society of Nephrology's Kidney Week 2014 , which takes place November 13th-16th at the Pennsylvania Convention Center in Philadelphia, PA. Poster #TH-PO730, titled " Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects wth Pruritus, " reports that Nalbuphine administered as oral nalbuphine HCl ER tablets was safe and well tolerated up to 240 mgs and that there appeared to be a dose-dependent reduction in VAS scores related to itch.

    Comment?

  12. TPG Biotech backs Trevi TherapeuticsRead the original story w/Photo

    Nov 7, 2014 | PE Hub

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  13. Trevi Therapeutics Announces Second Closing of $26 Million Series B...Read the original story

    Nov 5, 2014 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors. The Company is continuing enrollment in the U.S. for its uremic pruritus trial, a pivotal study expected to enroll approximately 360 patients, and expects to initiate enrollment at European sites for this study by year-end.

    Comment?

  14. Trevi Therapeutics Reels In $26 MillionRead the original story

    Nov 6, 2014 | BioSpace

    Trevi Therapeutics Announces Second Closing of $26 Million Series B Financing for Development of Nalbuphine ER Uremic pruritus trial enrolling ahead of schedule and Company preparing to initiate trial in prurigo nodularis NEW HAVEN, Conn.-- --Trevi Therapeutics, Inc. , a development-stage biotechnology company developing Nalbuphine ER for severe chronic pruritus conditions, today announced the second and final closing of $11 million in a Series B financing of $26 million led by TPG Biotech, the life science venture investment arm of TPG, and existing angel investors.

    Comment?

  15. Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global,...Read the original story

    Oct 29, 2014 | PRWeb

    DeepResearchReports.com adds "2014 Deep Research Report on Global and China Naltrexone HCL Industry" and "2014 Deep Research Report on Global and China Nalbuphine HCL Industry" to its research database. 2014 Deep Research Report on Global and China Naltrexone HCL Industry" is a professional and in-depth research report on the China Naltrexone HCLmarket.

    Comment?

  16. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Oct 29, 2014 | Business Wire

    The notes will constitute direct, unconditional and uns... )--FUND A db x-trackers StoxxA Europe 600 Oil & Gas Short Daily UCITS ETF DEALING DATE A 28-Oct-14 NAV PER SHARE A EUR17.9062 NUMBER OF SHARES IN ISSUE A 210,623 CODE A )--SOFC component/system developer and manufacturer WATT Fuel Cell Corp., announces the official grand opening of its new facility in Mt. Pleasant, Penn.

    Comment?

  17. Research and Markets: Global and Chinese Nalbuphine HCL Industry Report 2014Read the original story

    Oct 29, 2014 | Business Wire

    Global and Chinese Nalbuphine HCL Industry Report 2014 is a professional and in-depth study on the current state of the global Nalbuphine HCLindustry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.

    Comment?

  18. Gil Yosipovitch, M.D. Joins Trevi Therapeutics??? Clinical Advisory BoardRead the original story

    Oct 1, 2014 | BioSpace

    Trevi Therapeutics, Inc. , a late-stage development biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that Gil Yosipovitch, M.D. has joined its Clinical Advisory Board. In that role, Dr. Yosipovitch, Professor and Chair of The Department of Dermatology and Director of the Temple Itch Center at the Temple University School of Medicine in Philadelphia, Pennsylvania, will work closely with Trevi's Co-founders, Jennifer Good and Thomas Sciascia, M.D., on the Company's development programs.

    Comment?

  19. Gil Yosipovitch, M.D. Joins Trevi Therapeutics' Clinical Advisory BoardRead the original story

    Oct 1, 2014 | Freshnews

    Trevi Therapeutics, Inc. , a late-stage development biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced that Gil Yosipovitch, M.D. has joined its Clinical Advisory Board. In that role, Dr. Yosipovitch, Professor and Chair of The Department of Dermatology and Director of the Temple Itch Center at the Temple University School of Medicine in Philadelphia, Pennsylvania, will work closely with Trevi's Co-founders, Jennifer Good and Thomas Sciascia, M.D., on the Company's development programs.

    Comment?

  20. Trevi Therapeutics Selected to Exhibit Poster at 2014 Annual Meeting...Read the original story

    Sep 17, 2014 | Hispanic Business

    This rigorous study characterized the pharmacokinetics of Nalbuphine ER in renally impaired patients, established that the drug was well tolerated across the entire dose range, and demonstrated the drug is not affected by the dialysis process. We also observed compelling proof-of-concept data in the reduction of itching over the two-week period in the hemodialysis patients.

    Comment?